The PE Ratio as of December 2024 (TTM) for INmune Bio, Inc. (INMB) is -2.09

According to INmune Bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.09. This represents a change of -51.22% compared to the average of -4.28 of the last 4 quarters.

INmune Bio, Inc. (INMB) Historical PE Ratio (quarterly & annually)

How has INMB PE Ratio performed in the past?

The mean historical PE Ratio of INmune Bio, Inc. over the last ten years is -256.91. The current -2.09 PE Ratio has changed -18.65% with respect to the historical average. Over the past ten years (40 quarters), INMB's PE Ratio was at its highest in in the March 2017 quarter at 341.04. The PE Ratio was at its lowest in in the September 2016 quarter at -184.29.

INmune Bio, Inc. (INMB) PE Ratio by Quarter and Year

Discovering the peaks and valleys of INmune Bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

INmune Bio, Inc. (INMB) Average PE Ratio

How has INMB PE Ratio performed in the past?

The current PE Ratio of INmune Bio, Inc. (INMB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

INmune Bio, Inc. (INMB) PE Ratio vs. Peers

How is INMB’s PE Ratio compared to its peers?

INmune Bio, Inc.’s PE Ratio is less than TFF Pharmaceuticals, Inc. (-0.02), greater than Anebulo Pharmaceuticals, Inc. (-4.09), less than Abcam plc (578.45), less than AN2 Therapeutics, Inc. (-0.69), less than Cue Biopharma, Inc. (-1.19), greater than Anixa Biosciences, Inc. (-6.69), less than IN8bio, Inc. (-0.36), less than PolyPid Ltd. (-0.87), less than Aerovate Therapeutics, Inc. (-0.87), less than Eliem Therapeutics, Inc. (0), less than Decibel Therapeutics, Inc. (-1.95), greater than Anavex Life Sciences Corp. (-22.76), greater than Cassava Sciences, Inc. (-6.55), less than BioVie Inc. (-0.50), less than Cognition Therapeutics, Inc. (-0.72), greater than TScan Therapeutics, Inc. (-3.21), less than Dermata Therapeutics, Inc. (-0.17),

Build a custom stock screener for INmune Bio, Inc. (INMB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like INmune Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

INmune Bio, Inc. (INMB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like INmune Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.